Japan approves Novartis’ oral MS drug Gilenya
Japan approves Novartis’ oral MS drug Gilenya
Japanese regulatory authorities have approved Novartis’ once-daily multiple sclerosis (MS) drug Gilenya.
The Gilenya sanction covers use of the drug for preventing relapse and delaying progression of physical disability in adult MS patients.
The only other drug licensed in Japan for preventing relapse of MS patients is interferon beta. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 171 Views
-
Last post by NHE
-
- 5 Replies
- 14898 Views
-
Last post by gibbledygook
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 0 Replies
- 560 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif
-
- 0 Replies
- 170 Views
-
Last post by DIM
-
- 2 Replies
- 1114 Views
-
Last post by DIM
-
- 1 Replies
- 2016 Views
-
Last post by raceya